San Francisco startup Construction Therapeutics is usually focusing on an oral, the moment-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-stage analyze showed regular weight loss of about six% and it programs to start A furt